EVALUATING THE ECONOMIC HEALTH : ANALYSING FINANCIAL PERFORMANCE OF INDIAN PHARMACEUTICAL GIANTS

Abstract

This study focuses on the crucial assessment of India's pharmaceutical industry, a key contributor to both the national economy and healthcare landscape. This research seeks to provide a comprehensive analysis of the financial performance of leading pharmaceutical companies in the country, shedding light on their overall financial well-being, growth patterns, and comparative standings within the industry. With the objective of understanding the financial health of these companies, the study pursues two primary goals. Firstly, it delves into an in-depth analysis of the financial performance of selected pharmaceutical enterprises. Secondly, it conducts a comparative examination of their financial standing, aiming to unearth potential variations in their financial strategies, operational efficiency, and competitive positioning. The study casts its spotlight on four prominent pharmaceutical companies: Cipla Ltd, Divis Laboratories Ltd, Dr Reddys Laboratories Ltd, and Sun Pharmaceutical Industries Ltd. By selecting these diverse entities, the research enables a comprehensive exploration of the entire spectrum of the pharmaceutical industry. Spanning a period of five years from 2018-19 to 2022-23, the study ensures a comprehensive evaluation of the companies' financial performance over a significant timeframe. This extended scope captures their responses to dynamic market shifts, evolving regulatory frameworks, and changing industry dynamics. To achieve its objectives, the study employs a combination of ratio analysis and ANOVA (Analysis of Variance) testing. Ratio analysis offers a detailed insight into various financial indicators such as net profit margin, return on net worth/equity, return on capital employed, and current ratio.